Trump’s Last-Minute Medicare Part D Rule Could Stand

On Jan. 19, the last full day of the Trump administration, CMS finalized a grab-bag rule that includes several drug pricing components. Experts tell AIS Health that the rule could tie the Biden administration to aspects of the Trump administration’s drug pricing agenda.

One requires Medicare Part D plans to offer a consumer-facing real-time benefit tool (RTBT) that grants enrollees instant formulary and benefit information, including an accurate estimate of their point-of-sale cost sharing. Another allows Part D plan sponsors to implement a second formulary tier for specialty drugs with a lower cost-sharing amount than their existing specialty tier beginning Jan. 1, 2022. The regulation also requires plans to report their internal, qualitative pharmacy evaluation data to CMS. Other notable elements of the rule include new requirements to address opioid overprescribing and misuse.

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today